Kernal Biologics

Kernal Biologics is a biotechnology startup based in the United States, founded in 2016. The company focuses on creating mRNA therapies to combat severe diseases, including cancer. Kernal's innovative approach involves instructing specific cells on how to produce their own drugs using mRNA. The team, with roots at MIT, Harvard, and significant experience in the mRNA space, has a track record of success, having previously built a thriving Biotech company. Their recent achievement includes securing a $25.00M Series A investment on 07 July 2022, with funding from a consortium of reputable investors such as Amgen Ventures, Civilization Ventures, Hummingbird Ventures, HBM Genomics, and Amino Collective. Kernal's focus on cutting-edge mRNA therapies places it at the forefront of the biotechnology, health, and pharmaceutical industries, positioning the company for potential growth and impact in the rapidly evolving healthcare landscape.